What type of company is Cytokinetics?
Cytokinetics is a late-stage biopharmaceutical enterprise dedicated to discovering, developing, and commercializing muscle biology-directed medicines for treating serious cardiovascular and neuromuscular diseases. The company pioneers muscle contractility research, focusing on innovative drug candidates designed to activate or inhibit specific muscle proteins to improve cardiac function in conditions like heart failure and hypertrophic cardiomyopathy, or to address muscle weakness in amyotrophic lateral sclerosis. Through targeted clinical development programs, Cytokinetics aims to provide breakthrough therapies that restore physical function and enhance quality of life for patients.
Related FAQs
Cytokinetics, Incorporated officially completed its initial public offering and began trading its common stock on the NASDAQ stock exchange under the ticker symbol CYTK on April 29, 2004.
Yes, Dominion Energy (D) pays a quarterly dividend to its shareholders.
Wall Street equity research analysts covering Cytokinetics, Incorporated (CYTK) establish a consensus 12-month average price target of approximately $99.37 to $105.00 per share.
The stock ticker symbol CYTK represents shares of Cytokinetics, Incorporated, which is a publicly traded biopharmaceutical enterprise listed on the Nasdaq stock exchange.
As of July 2026, the overwhelming consensus rating for Cytokinetics is a "Buy," with a significant percentage of analysts classifying it as a "Strong Buy".
Cytokinetics is widely considered a promising player in the biotechnology sector, garnering strong positive sentiment from market analysts who view its future prospects favorably.
Aficamten (marketed under brand names such as Myqorzo) has been authorized as a once-daily oral cardiac myosin inhibitor designed to treat symptomatic obstructive hypertrophic cardiomyopathy.
No, Cytokinetics (CYTK) does not pay dividends. As a growth-focused biotechnology company, it prioritizes the reinvestment of all available capital into its research, development, and commercialization efforts.
Diodes Incorporated records annual revenues scaling between USD 1.3 billion and USD 1.6 billion, positioning the company as a leading global manufacturer and supplier of high-quality discrete, analog, and semiconductor products.
Construction firms operating under names matching D Construction represent regional engineering, heavy civil contracting, and commercial building enterprises holding multi-million-dollar asset valuations.
The professional analyst consensus for Cytokinetics is a "Strong Buy," with virtually all covering analysts recommending that investors buy or hold the stock rather than sell.
Dacotah Bank is an established regional financial institution headquartered in Aberdeen, South Dakota, maintaining total consolidated assets exceeding $3.1 billion.
Cytokinetics has developed key cardiovascular drug candidates, notably aficamten (marketed under the brand name MYQORZO), which is a cardiac myosin inhibitor designed for the treatment of adults with symptomatic obstructive hypertrophic cardiomyop...
Market analyst consensus ratings for Tetra Tech, trading under the ticker symbol TTEK, generally feature favorable buy or hold recommendations as equity researchers evaluate robust demand for environmental engineering, water management, and sustai...
Cytokinetics is a specialty cardiovascular biopharmaceutical company focused on pioneering scientific innovations in muscle biology and developing potential new medicines for patients suffering from diseases of cardiac muscle dysfunction.